GLENMARK Glenmark Pharmaceuticals Ltd. — Smart-Money Activity, F&O Buildup & Bulk Deals
Sector: HealthcareSmart Money Verdict synthesis of derivatives, deals, and promoter files
Analysis what the data is telling us about GLENMARK
In the last completed session, Glenmark Pharmaceuticals Ltd. closed -4.04% with futures open interest moving +0.3%. Positioning is neutral — neither side is decisively adding or unwinding right now. The stock's option PCR sits at 0.53, indicating heavy call-side writing — option dealers see resistance overhead. Max-pain strike at ₹2,300 sits 4.9% above the current price, a mild magnet near expiry.
There have been no notable bulk or block deals from FIIs, mutual funds, or insurance companies in Glenmark Pharmaceuticals Ltd. over the last 30 sessions.
Putting it together, the smart-money picture for Glenmark Pharmaceuticals Ltd. is balanced between accumulation and distribution forces.
F&O Positioning EOD derivatives setup
Quote Details key metrics & weights
Technical Snapshot as of 2026-10-08 close · from 400 sessions of price history
Key Fundamentals headline ratios · Healthcare
Fundamental ratios sourced from public market data, refreshed periodically; verify against company filings before relying on them.
Institutional Deals last 30 sessions (bulk & block)
Insider & Promoter Filings last 60 days
Option Chain Ladder nearest expiry 2026-10-27 · spot 2,192 · EOD 2026-10-08
| Call OI (writers) | Strike | Put OI (writers) |
|---|---|---|
|
IV 82%
Δ 0.65
θ -4.2
ν 2
|
2080 |
IV 32%
Δ -0.21
θ -1.1
ν 1
|
|
IV 153%
Δ 0.62
θ -7.9
ν 2
|
2100 |
IV 32%
Δ -0.25
θ -1.2
ν 2
|
|
IV 82%
Δ 0.61
θ -4.3
ν 2
|
2120 |
IV 30%
Δ -0.29
θ -1.2
ν 2
|
|
IV 147%
Δ 0.60
θ -7.7
ν 2
|
2140 |
IV 30%
Δ -0.33
θ -1.3
ν 2
|
|
IV 82%
Δ 0.58
θ -4.4
ν 2
|
2160 |
IV 30%
Δ -0.38
θ -1.3
ν 2
|
|
IV 141%
Δ 0.57
θ -7.4
ν 2
|
2180 |
IV 29%
Δ -0.43
θ -1.3
ν 2
|
|
IV 30%
Δ 0.51
θ -1.8
ν 2
|
2200 S |
IV 28%
Δ -0.49
θ -1.2
ν 2
|
|
IV 135%
Δ 0.55
θ -7.2
ν 2
|
2220 |
IV 29%
Δ -0.54
θ -1.3
ν 2
|
|
IV 73%
Δ 0.49
θ -4.0
ν 2
|
2240 |
IV 28%
Δ -0.60
θ -1.2
ν 2
|
|
IV 30%
Δ 0.36
θ -1.6
ν 2
|
2260 |
IV 27%
Δ -0.66
θ -1.1
ν 2
|
|
IV 29%
Δ 0.31
θ -1.5
ν 2
|
2280 |
IV 28%
Δ -0.70
θ -1.0
ν 2
|
|
IV 30%
Δ 0.27
θ -1.4
ν 2
|
2300 MP |
IV 28%
Δ -0.74
θ -0.9
ν 2
|
|
IV 29%
Δ 0.22
θ -1.2
ν 1
|
2320 |
IV 26%
Δ -0.80
θ -0.6
ν 1
|
Chain Interpretation
Strategy Builder multi-leg payoff for GLENMARK options · 2026-10-27 expiry
Legs
Payoff at expiry
Latest News recent coverage from Reuters, Simply Wall St, MT Newswires and others
GLENMARK — frequently asked questions
What is the Glenmark Pharmaceuticals Ltd. share price today?
GLENMARK is trading at ₹2,192.20 (-3.95% vs previous close), per the latest update on this page.
What is the P/E ratio of Glenmark Pharmaceuticals Ltd.?
GLENMARK (Glenmark Pharmaceuticals Ltd.) has a trailing twelve-month P/E ratio of 34.4.
What is the market cap of Glenmark Pharmaceuticals Ltd.?
GLENMARK has a market capitalisation of approximately ₹61,869 crore.
Is GLENMARK near its 52-week high?
GLENMARK is trading -13.6% from its 52-week high of ₹2,537.60 as of 2026-10-08.
What is the RSI of GLENMARK?
The 14-day RSI of GLENMARK is 32.4, which is considered neutral.
Is GLENMARK above its 200-day moving average?
GLENMARK is trading below its 200-DMA of ₹2,215.35 (-1.0% away).
What is the F&O buildup in GLENMARK?
The latest end-of-day derivatives data classifies GLENMARK as Neutral (bias: neutral), based on the day's combined price and open-interest change.
What is the max pain and PCR for GLENMARK options?
GLENMARK's option-chain max pain strike is ₹2,300 and its put-call ratio (OI) is 0.53, from the latest end-of-day option chain.
Are FIIs or big investors buying GLENMARK?
Strota tracks every bulk and block deal in GLENMARK with named buyers and sellers, plus promoter and insider filings — the tables on this page list the most recent institutional activity as disclosed to the exchanges.